



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1735-B (400/140))

In the Application of:

Lockridge et al.

Serial No.: 10/726,236

Filing Date: December 2, 2003

For: Nucleic Acid-Based Modulation of Gene
Expression in the Vascular Endothelial
Growth Factor Pathway

Examiner: TBA

Group Art Unit: 1635

Confirmation No.: 4026

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Supplemental Information Disclosure Statement;
- ☒ Supplemental Information Disclosure Statement (IDS) PTO-1449 Form; and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on October 11, 2005.

By :

Anita J. Terpstra
Reg. No. 47,132



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1735-B (400/140))**

In the Application of:)	
)	
Lockridge et al.)	
)	Examiner: TBA
Serial No.: 10/726,236)	
)	Group Art Unit: 1635
Filing Date: December 2, 2003)	
)	Confirmation No.: 4026
For: Nucleic Acid-Based Modulation of Gene)	
Expression in the Vascular Endothelial)	
Growth Factor Pathway)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. This application is a continuation-in-part of US Serial No. 10/306,747 filed November 27, 2002 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 CFR §1.98(d), all references have been previously cited and submitted to the Patent and Trademark Office with the prior application US Serial No. 10/306,747 and no references are enclosed herein.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: October 11 2005

By: 

Anita J. Terpstra
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	08/878,640	06/19/97	Ludwig et al.			
	*	09/205,520	12/03/99	Sullenger et al.			
	*	09/476,387	12/30/99	Beigelman et al.			
	*	09/870,161	05/29/01	Pavco et al.			
	*	09/877,526	06/08/01	Usman et al.			
	*	09/918,728	07/31/01	Beigelman et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/101,174	09/21/98	Hartmann et al.			
	*	US 2003/0190635	10/2003	McSwiggen et al.			
	*	US 2003/0206887	11/2003	Morrissey et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,987,071	01/22/91	Cech et al.			
	*	5,270,163	12/14/93	Gold et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

	*	5,334,711	08/02/94	Sproat et al.			
	*	5,475,096	12/12/95	Gold et al.			
	*	5,525,468	06/11/96	McSwiggen et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,741,679	04/21/98	George et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,807,718	09/15/98	Joyce et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,854,038	12/29/98	Sullenger and Cech			
	*	5,871,914	02/16/99	Nathan et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

	*	5,898,031	04/27/99	Crooke			
	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/1999	Matulic-Adamic et al.			
	*	6,001,311	12/14/99	Brennan et al.			
	*	6,005,087	12/21/99	Cook et al.			
	*	6,107,094	08/22/00	Crooke			
	*	6,127,173	10/03/00	Eckstein et al.			
	*	6,159,714	12/12/00	Usman et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,300,074	10/09/01	Gold et al.			
	*	6,346,398	02/12/2	Pavco et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,482,932	11/19/02	Beigelman et al.			
	*	6,506,559	01/14/03	Fire et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

	*	2,359,180	08/03/00	CA (Kreutzer et al.)				
	*	1 325 955	07/09/03	EP (Klippel-Giese et al.)				
	*	08208687	08/1996	JP (Hotoda et al.)				
	*	90/14090	05/19/89	WO (Gillespie et al.)				
	*	94/01550	01/20/94	WO (Agrawal et al.)				
	*	97/21808	06/19/97	WO (Robinson)				
	*	99/49029	09/30/99	WO (Graham et al.)				
	*	99/53050	10/21/99	WO (Waterhouse et al.)				
	*	99/61631	12/02/99	WO (Heifetz et al.)				
	*	00/49035	08/24/00	WO (Sheen)				
	*	00/63364	10/26/00	WO (Pachuk et al.)				
	*	01/097850	12/27/01	WO (Siemeister et al.)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	*	02/07747	01/31/02	WO (King)				
	*	02/096927	12/05/02	WO (Escobedo et al.)				
	*	02/10378	02/07/02	WO (Cowser et al.)				
	*	02/22636	03/21/02	WO (Bennett et al.)				
	*	03/068797	08/21/03	WO (Rossi et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

	*	03/070887	08/28/03	WO (McSwiggen et al.)				
	*	03/070896	08/28/03	WO (McSwiggen et al.)				
	*	03/070910	08/28/03	WO (McSwiggen et al.)				
	*	03/074654	09/12/03	WO (McSwiggen et al.)				
	*	03/080638	10/02/03	WO (Lacasse et al.)				
	*	04/009769	01/29/04	WO (Tolentino et al.)				
	*	04/043977	05/27/04	WO (Prakush et al.)				
	*	04/072261	08/26/04	WO (Li et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	*	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
	*	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
	*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	*	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999)
*	International Search Report for PCT/US03/05022 mailed January 6, 2005
*	International Search Report for PCT/US03/05028 mailed October 17, 2003
*	International Search Report for PCT/US03/05346 mailed October 17, 2003
*	International Search Report for PCT/US2004/016390 mailed March 31, 2005
*	International Search Report for PCT/US2004/027403 mailed July 12, 2005
*	International Search Report for PCT/US2004/30488 mailed January 12, 2005
*	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
*	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
*	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
*	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
*	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF and VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, S4-S5 (2003)
*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
*	Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

	*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
	*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999)
	*	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
	*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> , 95, 13959-13964 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.